More recently, there has been an increasing interest in AR agonist therapy after Hickey et al. undertook a large-scale study showing how AR can act as a tumor suppressor rather than driver in ER + BC, by opposing ER transcriptional activity [122]. Here, AR is linked to breast cancer.